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Available online 9 August 2016Physical interaction of skeletal precursors with multiple myeloma cells has been shown to suppress their osteo-
genic potential while favoring their tumor-promoting features. Although several transcriptome analyses of my-
eloma patient-derived mesenchymal stem cells have displayed differences compared to their healthy
counterparts, these analyses insufﬁciently reﬂect the signatures mediated by tumor cell contact, vary due to dif-
ferent methodologies, and lack results in lineage-committed precursors.
To determine tumor cell contact-mediated changes on skeletal precursors, we performed transcriptome analyses
of mesenchymal stem cells and osteogenic precursor cells cultured in contact with the myeloma cell line INA-6.
Comparative analyses conﬁrmed dysregulation of genes which code for known disease-relevant factors and ad-
ditionally revealed upregulation of genes that are associatedwith plasma cell homing, adhesion, osteoclastogen-
esis, and angiogenesis. Osteoclast-derived coupling factors, a dysregulated adipogenic potential, and an
imbalance in favor of anti-anabolic factors may play a role in the hampered osteoblast differentiation potential
of mesenchymal stem cells. Angiopoietin-Like 4 (ANGPTL4) was selected from a list of differentially expressed
genes as a myeloma cell contact-dependent target in skeletal precursor cells which warranted further functional
analyses. Adhesion assayswith full-length ANGPTL4-coated plates revealed a potential role of this protein in INA-
6 cell attachment.
This study expands knowledge of the myeloma cell contact-induced signature in the stromal compartment of
myelomatous bones and thus offers potential targets that may allow detection and treatment of myeloma
bone disease at an early stage.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
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Multiplemyeloma (MM) is a plasma cell neoplasia that is still largely
incurable, although themedian 10-year survival has increased to 40% in
patients b 50 years of age due to the development of new drugs and
bone marrow transplantation strategies during the last two decades
[1]. MM is preceded by the non-cancerous plasma cell neoplasmmono-
clonal gammopathy of undetermined signiﬁcance (MGUS) [2,3]. Pro-
gression to malignancy is driven, among other factors, by changes that
occur in the tumor microenvironment leading to enhanced angiogene-
sis, immunosuppression, and bone resorption [4]. Myeloma bone dis-
ease is the result of intensive interaction between myeloma cells and
the bone that often precipitates in osteolytic lesions, severe osteoporo-
sis with pathological fractures, and bonepain. Togetherwith other com-
plications such as hypercalcemia and paralysis, myeloma bone disease
has a very strong impact on the course of the disease, patient's quality
of life, and overall survival. Over long periods it may even be the domi-
nant determining factor for the individual burden and the clinical out-
come [5,6].
Myeloma bone disease is the result of disturbed bone remodeling
with enhanced osteoclastogenesis and decreased bone formation. The
molecular mechanisms have been partly unraveled, in analogy to bone
metastases from other solid tumors like breast and prostate cancer.
Tumor-derived signaling substances, such as receptor activator of NF-
κB ligand (RANKL), directly or indirectly stimulate osteoclast activity
causing bone loss and pathological fractures. More recently, it has
been demonstrated that myeloma and other tumor cells also produce
factors inhibitory for osteogenic differentiation and bone formation,
such as inhibitors of the Wnt signaling pathway dickkopf (DKK)-1 and
sclerostin, which results in completely abolished anabolic bone metab-
olism and regeneration [6,7,8]. Besides soluble factors, physical interac-
tion between myeloma and mesenchymal stem cells (MSC) or
osteogenic precursor cells (OPC) leads to a hampered osteoblast differ-
entiation of the skeletal precursor cells [9] which can be partially re-
stored by the anti-cancer agent and proteasome inhibitor bortezomib
[10].
MSC have been reported to inhibit myeloma progression via pro-ap-
optotic mechanisms [11], but generally, their role in myeloma develop-
ment and survival is described as a supportive one [12,13,14,15,16].
Comparison of gene expression proﬁles between MSC from MGUS pa-
tients/healthy donors with those from MM patients demonstrate
tumor-promoting abnormalities in the latter [17,18]. The support of
MM development by MSC may be genuine and intrinsic, e.g. as part of
genetic predisposition. However, several studies revealed that signature
changes of MSC are also acquirable by physical contact with myeloma
cells [19] (unpublished results from Herman and colleagues: cited in
[18]). Nonetheless, genome-wide analyses of MM cell contact-induced
changes in theMSC transcriptome are scarcely published [18,19]. More-
over, to our knowledge, no study has been performedwithMSC-derived
osteogenic precursors, although it is known that their osteogenic poten-
tial is also suppressed by direct interaction with MM cells [9].
Therefore, we performed a thorough transcriptome analysis of both
MSC andOPC after direct contactwithMMcells. These results show that
OPC are also capable of supportingMMprogression, albeit to a lesser ex-
tent than MSC, which seem to have a greater tumor-promoting poten-
tial according to the genetic signature. Besides a general overview of
altered signaling pathways that support the importance of bone-
forming cells in myeloma bone disease the data indicate that osteogen-
esis and angiogenesis may be uncoupled at the bone-tumor interface.
Furthermore we identiﬁed Angiopoietin-Like 4 (ANGPTL4) as a novel in-
teraction-speciﬁc target of skeletal precursors that mediates myeloma
cell attachment. These data support the potent role of stroma in patho-
physiological mechanisms favoring MM bone disease and provide in-
sights into molecular mechanisms and signaling pathways that are
associated with the development of bone metastases and niche
hijacking in general.2. Materials and methods
2.1. Ethics statement
Bonematerial was used in accordancewith the local Ethics Commit-
tee of the Medical Faculty of the University of Würzburg with written,
informed consent of each patient.
2.2. Cells and cell culture
2.2.1. Primary cells and cell lines
Primary humanMSCwere isolated from the cancellous bone from the
acetabulum received fromdonors after total hip arthroplasty (gender: 11
females, 13male; average donor age in years:mean±SD: 63±9; range:
48–77 years).MSCwere isolated by surface adherence and characterized
as previously described [20,21,22]. Expansion was performed in DMEM/
Ham's F-12 (1:1) medium (Life Technologies GmbH, Darmstadt, Germa-
ny), supplementedwith 10% (v/v) fetal calf serum (FCS) (Biochrom, Ber-
lin, Germany), 100 U/ml penicillin, 100 μg/ml streptomycin (Life
Technologies GmbH) and 50 μg/ml L-Ascorbic acid 2-phosphate
(Sigma-Aldrich Chemie GmbH (Sigma), Schnelldorf, Germany). MSC
were passaged at least once before they were used for experiments.
The plasmacytoma cell line INA-6 [23] was authenticated by DNA
proﬁling using 8 different highly polymorphic short tandem repeat
loci (performed at the Leibniz Institute, Braunschweig, Germany). For
cultivation, cells were incubated in RPMI 1640 medium (Life Technolo-
gies GmbH) supplementedwith 20% (v/v) FCS, 100 μg/ml gentamicin, 2
mmol/l L-glutamine (Life Technologies GmbH), 1 mmol/l sodium pyru-
vate (Sigma), and 2 ng/ml recombinant human interleukin-6 (IL-6; R&D
Systems,Wiesbaden, Germany). In case of experiments comprisingMSC
and OPC, INA-6 cells were washed with PBS and resuspended in the re-
spective propagation medium without IL-6 before used for co-culture
studies [24]. OPM-2 [25], MM.1S [26], AMO1 [27], and U266 cells [28]
were propagated and cultivated in RPMI1640 medium comprising 10%
(v/v) FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mmol/l L-glu-
tamine, and 1 mmol/l sodium pyruvate.
CD19+ B-cells were used as a control for myeloma cell lines as pre-
viously published [29]. Primary CD19+ B-cells were puriﬁed from pe-
ripheral blood mononuclear cells (PBMCs) by magnetic activated cell
sorting (MACS) (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
PBMCs were obtained by ﬁcoll density centrifugation of leukocyte con-
centrate. Leukocyte concentrate fromwhole blood donation (purchased
from the Blood Donation Service of the Bavarian Red Cross,
Wiesentheid, Germany) was diluted 1:1 (v/v) by PBS, coated onto
Ficoll® Paque Plus (GE Healthcare Europe GmbH, Munich, Germany)
in a ratio of 2:1, and centrifuged for 30min (609g, brake off). The inter-
phasewaswashed with PBS buffer comprising 0.9% (w/v) sodium chlo-
ride (AppliChem GmbH, Darmstadt, Germany), 1% (v/v) FCS, and 2 mM
EDTA (AppliChem GmbH). Isolation of CD19+ B-cells was performed
according to the manufacturer's instructions using CD19 MicroBeads
and LS columns (Miltenyi Biotec GmbH). CD19+ B-cells were incubated
in RPMI1640 medium, 10% (v/v) FCS, 100 U/ml penicillin, 100 μg/ml
streptomycin, 2 mmol/l L-glutamine, and 50 μmol/l beta-
mercaptoethanol (Life Technologies GmbH) for one day prior to the
experiments.
2.2.2. Differentiation of MSC to OPC
For differentiation of MSC to OPC, MSC were incubated for two
weekswith DMEMHigh Glucosemedium (Life Technologies GmbH) in-
cluding 10% (v/v) FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, and
additionally supplemented with 10 mmol/l beta-glycerophosphate
(Sigma), 100 nmol/l dexamethasone (Sigma), and 50 μg/ml L-Ascorbic
acid-2-phosphate (Sigma). Osteogenic differentiation medium and
DMEM High Glucose medium (control) were changed every 3 to
4 days. Osteogenic differentiationwas demonstrated by staining of alka-
line phosphatase (ALP) and mineralized extracellular matrix using
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Phosphatase, Leukocyte Kit 86-C (Sigma) according to the
manufacturer's instructions. For alizarin red S staining, cell monolayers
were ﬁxed with ice-cold methanol (Carl Roth GmbH & Co. KG, Karlsru-
he, Germany) and incubated for 2 min in 1% (w/v) alizarin red S
(Sigma)/0.25% (v/v) ammonia (Merck KGaA, Darmstadt, Germany)
staining solution. Stained monolayers were washed with distilled H2O
and embedded in mounting media (Tissue-Tek, Sakura, purchased
from A. Hartenstein GmbH, Würzburg, Germany), before being exam-
ined microscopically. Alizarin Red S and ALP stainings of OPC, which
had also been used for preparation of the OPC microarray specimens,
are displayed as supplementary data (Supplemental Fig. 1).
2.2.3. Differentiation of MSC to OPC under co-culture with INA-6 cells
To investigate the effect of INA-6 cell contact on osteogenic differen-
tiation of MSC, MSC were co-cultured with INA-6 cells while differenti-
ating to the osteogenic lineage for 14 days. The protocol was similar to
the procedure described by Giuliani et al. [9]. Brieﬂy, 5 × 105 MSC
were seeded per well (6-well cell culture plate) and allowed to attach
overnight. The following day (day 1), 2 × 105 INA-6 cells per well
were added and osteogenic differentiation was initiated by incubating
the co-culture with osteogenic differentiation medium. Every third
day, 50% of mediumwas changed. On day 15, co-cultures were washed
with PBS and monolayers were stained for active ALP.
2.2.4. Co-culture of myeloma cells or B-cells with MSC or OPC
MSC (passage 0) were detached with 0.05% trypsin/EDTA (Life Tech-
nologies GmbH) at 70–90% conﬂuency and re-seeded with 5 × 104
cells/cm2 in 175 cm2 cell culture ﬂasks (for microarray sample prepara-
tion) or in 6-well cell culture plates (for all other experiments). In the
case of OPC, osteogenic differentiation started the following day (day
1) as described above. For co-culture studies with myeloma cells, MSC
and OPC were adapted to cell culturing conditions by incubating them
with a 1:1 (v/v)mixture ofMSC/myeloma cellmediumandOPC/myelo-
ma cell medium for 24 h at day 1 or day 15, respectively. For co-culture
studieswith B-cells, MSCwere incubated for 1 daywith a 1:1 (v/v)mix-
ture of MSC/B-cell medium. The day after, bone-forming cells were co-
cultured with CellTracker® Green 5-chloromethylﬂuorescein diacetate
(5 μmol/l) (CMFDA; Lonza Group, Basel, Switzerland)-stainedmyeloma
cells (2 × 106 cells in total, volume: 5 ml, 6-well cell culture plate; 3.5 ×
107 cells in total, volume: 90 ml, 175 cm2 cell culture ﬂask) or B-cells
(1.2 × 107 cells in total, volume: 5 ml, 6-well cell culture plate), resus-
pended in the respective 1:1 (v/v) media mixture. The CMFDA staining
and co-culture procedure have been performed as recently described
[30]. After 24 h, co-cultures were trypsinized and separated by ﬂuores-
cence activated cell sorting (FACS) (BD FACSAria™ III cell sorter, Becton
Dickinson GmbH, Heidelberg, Germany; performed at the Cell sorting
core facility, Institute of Virology and Immunobiology, University of
Würzburg; for microarray sample preparation) or by MACS (for all re-
maining experiments) using LD columns, CD45 MicroBeads (for INA-6
cells), CD38 and CD138 MicroBeads (for all remaining myeloma cell
lines), or CD19 MicroBeads (for B-cells) according to manufacturer's
instructions. Purity of CMFDA-negative MSC and OPC fractionswere es-
timated by post-sort analysis (for FACS-separated cells) or microscopi-
cally (forMACS-separated cells). The respective control cells underwent
the same procedure.
The indirect co-culture studies were performed according to the di-
rect co-culture protocol described above in 6-well cell culture plates
using transwell inserts of 0.4 μm pore membrane (Corning Inc. pur-
chased from VWR International GmbH Darmstadt Germany) and by
seeding INA-6 cells on top of the membrane.
2.2.5. Adhesion assay
The assay was performed similarly to the protocol that has been de-
scribed for INA-6 cells byHolt et al. [31]. Brieﬂy, white, clear-bottom 96-
well cell culture plates (Greiner Bio-One GmbH, Frickenhausen,Germany) were washed once with 100 μl distilled H2O per well and
supplemented with the solution of recombinant ANGPTL4 protein
(ANGPTL4 full-length, R&D systems) or 1% bovine serum albumin
(BSA) (control; Sigma). After incubation overnight, the wells were
blocked with 1% BSA for 1 h, andwashed three timeswith 100 μl hank's
buffered salt solution (HBSS). INA-6 cells, starved for 1 h by incubating
in RPMI 1640 medium without FCS and IL-6, were washed with HBSS
two times, seeded in HBSS (5 × 104 cells/well), and allowed to attach
for an additional 1 h at 37 °C and 5% CO2. Following one washing step,
adherent cells were quantiﬁed with the CellTiter-Glo® assay (Promega
GmbH, Mannheim, Germany) according tomanufacturer's instructions.
2.3. Isolation of total RNA and synthesis of cDNA
Isolation of total RNA was performed with the NucleoSpin® RNA II
kit (Machery-Nagel GmbH & Co. KG, Düren, Germany) according to
the manufacturer's instructions. Brieﬂy, synthesis of cDNA was carried
out with 1 μg of total RNA, 1 μg of random primers (Life Technologies
GmbH) or 50 pmol of oligo(dT)15 primers (Promega GmbH), and
200 U of moloney murine leukemia virus reverse transcriptase (RT)
(Promega GmbH) according to the manufacturer's instructions.
2.4. Semi-quantitative RT PCR analysis
The primers (listed in Supplemental Table 1) were created with the
online software Primer3Plus. The PCRmastermixwas composed as pre-
viously described [32]. PCR analyses were run in a peqSTAR 2×
thermocycler (Peqlab Biotechnologie GmbH, Erlangen, Germany) ac-
cording to the following protocol: 1) 95 °C for 2 min, 2) 95 °C for 30 s,
3) annealing temperature (TA) (primer speciﬁc, see Supplemental
Table 1 for TA) for 30 s, 4) 72 °C for 1 min, 5) 72 °C for 5 min, 6) chilled
to 4 °C. PCR products were separated by agarose gel electrophoresis (2%
agarose/0.5× GelRed® (Genaxxon Bioscience GmbH, Ulm, Germany)).
Quantitation of the respective PCR band was performed
densitometrically with the softwares Bio 1D (LTF, Wasserburg, Germa-
ny) and ImageJ (ImageJ 1.47; National Institutes of Health, Bethesda,
MD, USA). Data were normalized to the expression level of the house-
keeping gene EEF1A1. Speciﬁcity of PCR products was validated by se-
quence analyses using the BigDye Terminator v3.1 cycle sequencing
kit (Life Technologies GmbH) and ABI 3130xL Genetic Analyzer (Ap-
plied Biosystems, Darmstadt, Germany; sequencing was conducted by
the Institute of Human Genetics, University of Würzburg). Sequence
data alignment was performed using the software BioEdit (Tom Hall,
Ibis Therapeutics, Carlsbad, CA, USA) and the NCBI/Primer BLAST
database.
2.5. Microarray analysis
Total RNA of co-cultured MSC and OPC as well as of the respective
controls (each n = 5) were used for whole genome array analysis
(Affymetrix, High Wycombe, United Kingdom; performed at the Insti-
tute of Cell Biology (Tumor Research), University of Duisburg-Essen).
RNA (approximately 200 ng) was labeled with the GeneChip 3′ IVT Ex-
press Kit according to themanufacturer's instructions. Fragmentation of
cRNA was followed by 16 h hybridization of 10 μg sample at 45 °C on
Affymetrix HG-U133 Plus 2.0 GeneChips, washing as well as staining
using the Affymetrix Hybridization, Wash and Stain Kit and the
Affymetrix Fluidics Station 450 (Affymetrix). Hybridization was record-
ed at 570 nm and analyzed with the Gene Chip Scanner 3000 with G7
update andGeneChipOperating Software 1.2, respectively (Affymetrix).
Raw data are accessible at NCBI's Gene Expression Omnibus database
through GEO accession number GSE87073. Raw data were processed
with the statistical software R and the respective packages as recently
described by Schlegelmilch et al. [33]. Probe sets with a log-Fold change
(Fc) ≥ 0.5 and a log-Fc ≤ −0.5 were determined to be differentially
expressed. The ClueGo plug-in for the software Cytoscape [34] was
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expressed probe sets with a log-Fc N 1.0 (upregulated functionally
grouped terms) or log-Fc b−0.5 (downregulated functionally grouped
terms).
2.6. Statistical analysis
Statistical tests were calculated with the software GraphPad Prism 6
(version 6.03; GraphPad Software, Inc., La Jolla, CA, USA). Analyses were
performed using two-tailed Mann-Whitney test (validation of microar-
ray analysis, direct co-culture with B-cells) or Kruskal-Wallis test with
Dunn's post-hoc test (direct vs. indirect co-culture, adhesion assay). Dif-
ferences were considered signiﬁcant for p ≤ 0.05 (*), p ≤ 0.01 (**), or
p ≤ 0.001 (***).
3. Results
3.1. Contact with INA-6 cells inhibits the osteogenic differentiation of MSC
To investigate the effect of myeloma cell contact on skeletal precur-
sor cells, we used the representative, MSC-dependent plasmacytoma
cell line INA-6 [23,24] for co-culture experiments.
Since myeloma cells are known to hamper osteogenic lineage com-
mitment of MSC [9], we ﬁrst investigated the effect of INA-6 cell contact
on the osteogenic commitment of MSC by staining active ALP in 2D co-
culture that had been incubated with osteogenic differentiation medi-
um for two weeks (Fig. 1A). While the amount of cells with active ALP
increased in the MSC monolayer that underwent osteogenic differenti-
ation, this effectwas abolished in the presence of INA-6 cells, conﬁrming
an inhibitory inﬂuence of INA-6 cells on the osteogenic potential ofMSC
and thus its suitability for co-culture studies.
3.2. Contact with INA-6 cells induces changes in the transcriptome of skel-
etal precursor cells
As there are age-dependent differences in the transcriptome of MSC
[35] and as MM is a disease of the elderly [36], we usedMSC from older
donors for our analyses. In addition to the experiments with MSC, we
performed co-culture studies with MSC-derived OPC. Although osteo-
genic differentiation of pre-osteoblasts has been shown to be blocked
by myeloma cell contact [9], to our knowledge no whole genome stud-
ies about MM cell contact-induced changes in the OPC transcriptome
has been published yet.
To investigate the inﬂuence ofmyeloma cell contact onMSC andOPC
transcriptomes, we performed 1 d co-culture studies comprising
CMFDA-positive INA-6 cells and unstained bone-forming cells (Fig.
1B). The following day, MSC and OPC were puriﬁed from adherent
INA-6 cells by FACS, gating the CMFDA-negative cells (Fig. 1C). Purity
of MSC and OPC fractionswas determined afterwards by post-sort anal-
ysis of the CMFDA-negative cell fractions (purity of MSC cell fractions:
98 ± 0.3% (mean ± SEM, n = 5); purity of OPC fractions: 98.9 ± 0.7%
(mean ± SEM, n = 5)). The obtained RNA specimens were used for
whole genome analyses.
A comparison between the transcriptome of co-cultured bone
forming cells with the transcriptome obtained for the respective con-
trols revealed INA-6 cell contact-induced changes in the gene expres-
sion of skeletal precursor cells (Fig. 2). In the case of MSC, 991 probe
sets (783 up- and 208 down-regulated probe sets) were detected to
be differentially expressed whereas co-cultured OPC harbored a
changed expression pattern of 552 probe sets (292 up- and 260
down-regulated probe sets). Both transcriptome analyses showed con-
sistent regulation in 181 probe sets (161 up- and 20 down-regulated
probe sets), while no probe set was regulated contrarily.
Comparative analysis of probe sets with log-Fc N 1.0 and log-
Fc b−0.5 displayed pathways that are differentially regulated (Supple-
mental Fig. 2 and Supplemental Fig. 3).Physical interaction with INA-6 cells changed the transcriptome of
MSC and OPC with regard to genes mediating an enhanced epithelial
differentiation, playing a role in lipid and cholesterol storage, as well
as cell-cell adhesion. Genes involved in DNA replication seem to be pref-
erentially downregulated in co-cultured OPC while contact of INA-6
cells induces expression of genes in MSC that are associated with the
impairment of osteoblast differentiation. In addition, upregulated path-
ways of MSC transcriptome analysis comprised B-cell receptor signal-
ing. Due to the fact that MSC and OPC fractions could not be
completely puriﬁed from INA-6 cells, differentially expressed probe
set lists were additionally reworked by comparing these data with liter-
ature from NCBI's database PubMed and another transcriptome analy-
ses comprising INA-6 cells (data not shown) to eliminate potentially
B-cell- and myeloma cell-speciﬁc genes from the lists.
3.3. INA-6 cell contact changes the molecular signatures of skeletal precur-
sors to a more tumor-promoting phenotype
Eleven genes were selected from each probe set list for re-evalua-
tion. Selected genes code for disease-relevant factors, such as vascular
endothelial growth factor A (VEGFA) [37], or give rise to a potential, tar-
getablemolecule and/or factor that is of relevance in bone and/or tumor
biology (genes and abbreviations are listed in Supplemental Table 1).
Differential expression of the mRNA transcripts was conﬁrmed for mi-
croarray specimens by semi-quantitative RT-PCR using sequence-spe-
ciﬁc primers and densitometric analysis (Fig. 3). To investigate
whether the transcriptional dysregulation of selected genes is transfer-
rable to bone-forming cells that have been in contact with other myelo-
ma cell lines, we performed additional co-culture studies with MSC as
well as OPC and the myeloma cell lines OPM-2, MM.1S, AMO1, and
U266 and investigated the gene expression (with the exception of the
recently published KISS1R [30]) of the specimens by PCR. In the case
of upregulated probe sets, we were able to conﬁrm an enhanced level
of mRNAs in the co-cultured MSC and co-cultured OPC compared to
the respective control cells for almost all selected genes,whereas the in-
tensity of mRNA upregulation was dependent on the respective myelo-
ma cell line used for co-culturing (Supplemental Figs. 4 and 5).
However, we were not able to verify a downregulation of MEOX2 and
FIGN in MSC and OPC that had been in contact with OPM-2, MM.1S,
AMO1, or U266 cells.
Database search of differentially expressed probe sets revealed that
INA-6 cell contact changed the gene expression proﬁles of skeletal pre-
cursor cells to a more tumor-promoting transcriptome since differen-
tially expressed genes are associated with disease activity and are
known to interferewith bonemetabolism (see Table 1 for abbreviations
and references). Several genes coding for factors (APLN, STC1) or recep-
tors/ligands (OSMR, MCHR1, SEMA4D, EFNB2) that exert anti-anabolic
actionwere upregulated after INA-6 cell contact, exclusively in undiffer-
entiated MSC.
Since bone-forming cells are important interaction partners of MM
cells throughout the course of the disease, we screened the lists for
genes that are associated with mechanisms of malignant progression
(see Table 2 for abbreviations and references). We noted an upregula-
tion of the potential homing factors CCL28 and CCL26 in co-cultured
MSC as well as OPC and OPC, respectively. As direct cell-cell contact to
MSC is implicated in chemoresistance of MM cells (reviewed in [38]),
the lists were scanned for genes coding for adhesion molecules. It is
known that leukocyte function-associated antigen-1 (LFA-1) is
expressed on myeloma cells and mediates adhesion to MSC by
interacting with the ligand ICAM1 [39]. In addition to ICAM1, the MSC
microarray list revealed an INA-6 cell contact-dependent upregulation
of LFA-1 ligand ICAM5 [40] and Col11A1. For OPC, the transcriptome
analysis revealed an enhanced expression of JAM2. Moreover, another
group of differentially expressed genes included those that code for
pro-angiogenic factors, such as VEGFA, PGF, and ANGPTL4. These
genes were expressed in co-cultured MSC and OPC, whereas the
Fig. 1.MSC-INA-6 cell co-culture. (A) Representative ALP stainings of undifferentiated MSC (control), MSC cultured in osteogenic medium (OPC), and MSC that underwent osteogenic
differentiation for two weeks while co-cultured with INA-6 cells (OPC + INA-6). Scale bar: 100 μm (B) Displayed are 24 h co-cultures showing CMFDA-positive INA-6 cells attached to
the MSC monolayer. Scale bar: 100 μm (C) Representative dot blots of pre- and post-sort FACS analyses are shown.
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analysis, a higher potential to stimulate endothelial cells. Additional-
ly, we detected an upregulation of genes that code for adipokines
(APLN, ANGPTL4), lipid storage proteins (PLIN2, HILPDA), and cho-
lesterol transporters (ABCA1, VLDLR). In accordance with the MSC
transcriptome, co-cultured OPC showed an induced expression of
genes that are involved in lipid storage and fat metabolism. Howev-
er, expression of several adipogenic transcription factors (KLF8, KLF9,
CEBPD) and prostaglandin E2 synthesis relevant genes (PTGS2,
PTGES, PLCG2) were exclusively upregulated in the undifferentiated
MSC.3.4. Upregulation of ANGPTL4 in MSC is mainly induced by direct cell-cell
contact with INA-6 cells but not with CD19+ B-cells
In further studies, we concentrated on ANGPTL4 since differential ex-
pression of this gene has not only been shown in our array results butalso in other independently performed transcriptome analyses com-
prising MM patient-derived MSC [17,41].
First, we were interested whether the differential expression of
ANGPTL4 is mediated by soluble factors or by direct cell-cell interaction.
Therefore, indirect co-culture experiments with MSC and INA-6 cells
using transwell inserts were performed in addition to direct co-culture
studies. Semi-quantitative RT-PCR analysis revealed that differential ex-
pression of ANGPTL4 in MSC is mainly mediated by physical interaction
with INA-6 cells. ThemRNA level of ANGPTL4was increased by 2-fold in
MSC after indirect co-culture with INA-6 cells while gene expression
was enhanced by 7-fold in directly co-cultured MSC (Fig. 4A).
Furthermore, we were interested whether differential expression of
ANGPTL4 is generally mediated by contact with B-cells. Therefore, ex-
pression analyses were performed with MSC specimens that were di-
rectly co-cultured with CD19+ B-cells, isolated from the blood of
healthy donors. Semi-quantitative RT-PCR analysis revealed no differ-
ential expression of ANGPTL4mRNA in co-cultured MSC compared to
the respective controls (Fig. 4B).
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Since ANGPTL4 is an extracellular matrix protein and known to me-
diate cell-matrix interaction (reviewed in [42]), we tested the role of
ANGPTL4 in MM cell adhesion. INA-6 cells were plated in wells that
had been coated with different concentrations (1, 2.5, 5, and 10 μg/ml)
of recombinant human ANGPTL4 protein (full-length). After 1 h of incu-
bation, the number of adherent INA-6 cells was increased in a concen-
tration-dependent manner. The amount of attached INA-6 cells was
signiﬁcantly enhanced by an average of 285% and 557% on 5 μg/ml
and 10 μ/ml ANGPTL4, respectively, compared to cells attached to con-
trol wells coated with BSA instead (Fig. 5).
4. Discussion
Results of the present study expand knowledge of signatures in skel-
etal precursor cells, coined by physical interaction with myeloma cells.
Our data show for the ﬁrst time, to the best of our knowledge, microar-
ray analysis of osteogenically pre-differentiated MSC (OPC) that had
been in contact with MM cells. These ﬁndings support the importance
of the crosstalk of MM cells with skeletal precursor cells for myeloma
bone disease development. Data reveal several novel mechanisms trig-
gered in MSC and OPC that may lead to misbalanced bone remodeling,
resulting in osteolytic bone loss with stunted bone regeneration.
Although the importance of direct cell-cell contact between skeletal
precursor and myeloma cells for myeloma bone disease is known,
whole genome analyses to evaluate myeloma cell contact-induced
changes in skeletal precursor cells are limited. Unpublished results
fromHerman and colleagues, cited in the reviewof Reagan andGhobrial
[18], revealed the development of speciﬁc signatures in MSC and mye-
loma cells after 18 h of co-culture. Garcia-Gomez and co-workers con-
ﬁrmed that MSC are inﬂuenced by 24 h contact with MM.1S myeloma
cells, resulting in a transcriptomewith enhanced tumor-promoting fea-
tures [19]. They performed direct co-culture studies in an elegant way
by seeding the top and bottom of transwell inserts (pore size: 1 μm)
with MM.1S andMSC, respectively [19]. In our hands, however, a direct
cell culture system based on transwell inserts (pore size: 0.4 μm) was
less efﬁcient in terms of gene regulation (data not shown) when com-
pared to physical contact without meshes between the cells. For this
reason, we followed the latter strategy although the separation of the
co-cultured cells is more challenging.
Using the plasmacytoma cell line INA-6, we were able to conﬁrm
that myeloma cell “barrier free” physical contact profoundly changes
the transcriptome of MSC. In addition to MSC, the OPC transcriptome
was also affected by physical interaction with INA-6 cells, although a
smaller number of targets were differentially regulated. Co-culture
with INA-6 cells changed the transcriptome ofMSC andOPCwith regard
to 991 and 552 probe sets, respectively. The weaker response of differ-
entiated cells is in line with a previous study showing that the tran-
scriptome of osteoblasts from myeloma patients with and without
osteolysis is less modulated compared to that of the MSC counterpart
[43]. The number of differentially expressed probe sets in co-cultured
OPC may be lower compared to co-cultured MSC, on the one hand,
due to higher inter-experimental variability mediated by differences
in the osteogenic potential and, on the other hand, by a lower adhesion
of myeloma cells to OPC that were already protected by initial mineral-
ization at time of co-culture. Nonetheless, INA-6 cells strongly adhere toFig. 2. Differential gene expression in MSC and OPC after INA-6 cell contact. (A) The Venn
diagram shows the distribution of genes that are up- and downregulated according to the
microarray analyses in MSC and OPC alone as well as in both cell types (depicted by the
intersection). (B–C) Heatmap of the 50 most signiﬁcantly up-regulated probe sets in (B)
MSC or (C) OPC specimens (each n = 5) after 24 h contact to INA-6 cells (co-culture) in
comparison to the respective control. Differential gene regulation is indicated by a color
scheme: Yellow and red color represents up- and downregulation of the probe set,
respectively.
Table 1
Differential expression of genes in skeletal precursor cells after 24 h INA-6 cell contact that are linked to MM or metastatic disease and dysregulated bone metabolism.
Symbol Gene name log-Fc
MSC
log-Fc
OPC
Reference
1.1 Genes coding factors that correlate with disease activity
VEGFA Vascular endothelial growth factor A 2.2 2.0 Level of VEGF correlates with disease activity markers. Bone marrow is
suggested as the major source for VEGF.
[58]
ANG Angiogenin, ribonuclease, RNase A family, 5 1.8 Serum level of ANG correlates negatively with survival rate of MM patients and
positively with inﬁltration of plasma cells into the bone marrow.
[49]
IL-16 Interleukin 16 1.3 Bone marrow of myeloma patients shows overexpression of IL-16. IL-16
supports myeloma cell growth via an autocrine loop as both the cytokine and
the receptors CD4 and/or CD9 were shown to be expressed by myeloma cells.
[48]
BMP8B Bone morphogenetic protein 8b 1.6 Elevated expression of BMP8B in the bone marrow of gastric cancer patients
correlates with metastatic disease.
[59]
ANGPTL4 Angiopoietin-like 4 3.0 2.0 Expression of ANGPTL4 correlates with esophageal squamous cell carcinoma as
well as the metastatic potential of oral squamous cell carcinoma and early
colorectal cancer to lymph nodes.
[60,61,62]
1.2 Genes coding factors that are associated with bone metabolism
APLN Apelin 1.1 Apelin knockout mice showed an increased bone mass by affecting osteoblast
proliferation and differentiation.
[63]
OSMR Oncostatin M receptor 1.0 Deﬁciency of osteoblasts for OSMR resulted in increased bone mass with
limited bone resorption and formation in mice.
[64]
MCHR1 Melanin-concentrating hormone receptor 1 2.5 MCHR1 (−/−) mice develop osteoporosis. [65]
STC1 Stanniocalcin-1 2.2 Expression of STC1 has a negative effect on bone mass and bone size. [66,67]
MEOX2 Mesenchyme Homeobox 2 −1.6 In vivo studies in mice showed that both homeobox genes MEOX1 andMEOX2
are necessary for the proper development of axial skeleton and skeletal
muscles.
[68]
FIGN Fidgetin −1.5 −1.1 Involved in mammalian development, including skeleton. [69]
ANGPTL4 Angiopoietin-like 4 3.0 2.0 ANGPTL4 is upregulated in high fracture bone of osteoporotic patients. [70]
SEMA4D Sema domain, immunoglobulin domain (Ig),
transmembrane domain (TM) and short cytoplasmic
domain, (semaphorin) 4D
1.1 Osteoclast-derived semaphorin 4D diminishes bone formation by acting via its
receptor Plexin-B1, expressed on osteoblasts.
[71]
EFNB2 Ephrin-B2 −1.6 Bidirectional signaling between ligand ephrin-B2, expressed on osteoclasts,
and EPH receptor B4, expressed on osteoblasts, regulates osteoclastogenesis
negatively while osteoblastogenesis is enhanced; overexpression of EPH
receptor B4 in osteoblasts resulted in a higher bone mass in transgenic mice.
[50]
OMD Osteomodulin −1.3 Overexpression of osteomodulin favors osteogenic differentiation of MC3T3E1
osteoblasts in vitro.
[72]
Fc = Fold change.
log-Fc MSC= log-Fc in array “MSC after INA-6 cell contact”.
log-Fc OPC = log-Fc in array “OPC after INA-6 cell contact”.
Indicated is the most differentially regulated probe set of the corresponding gene.
161J. Dotterweich et al. / Bone 93 (2016) 155–166MSC and OPC, which requires certain efforts for separation of both cell
types.
Except for a dysregulation of ANGPTL4, transcriptome analyses of
MSC from MM patients (MM-MSC), which have been published so far
[17,19,41,43], largely lack consistency to our results. In addition, it has
to be noted that comparisons of MM-MSC transcriptome analyses only
lead tominor overlaps, whichmay be the result of different experimen-
tal set-ups as discussed byAndre and colleagues [41]. Since harvesting of
MM-MSC is preceded by long-term cultivation and expansion, it is likely
that the published analyses comprising MM-MSC reﬂect a rather
inherited and epigenetically modiﬁed phenotype [44], while our studies
reproduce a physical contact-mediated proﬁle. Thus, our data support
the important inﬂuence of MM cell contact on MSC cell functions that
are relevant for the progression of the disease. Nonetheless, our data
show thatmRNA expression of co-cultured bone-forming cells differs be-
tween the myeloma cell lines that were used. Therefore, we assume that
the heterogeneity ofmyeloma [45] leads to diverse signatures in the bone
marrow.Whether such differences can be assigned tomyeloma subtypes
and risk groups remains to be dissected. It seems reasonable to evaluate,
in future research, whether speciﬁc myeloma cell-induced footprints in
the bone marrow correlate with a high-risk myeloma phenotype and at
the same time a high risk of developing myeloma bone disease.
According to our studies and the gene expression analyses, the bone-
forming cells are susceptible to MM cell contact. The results of the mi-
croarray analyses indicate that homing of MM cells to bone and bone
marrow induces newmolecules and signalingpathways in themicroen-
vironment. Transition of MGUS to MM is linked to changes in the bone
marrow microenvironment, including an increased attraction of MMcells to the bonemarrow (reviewed in [46]) and an enhanced angiogen-
esis [47]. The transcriptome proﬁles presented here reﬂect these dis-
ease-relevant processes including several differentially expressed
probe sets that code for (potential) homing factors (CCL26, CCL28), ad-
hesion molecules (ICAM1, ICAM5, Col11A1, JAM2), and pro-angiogenic
factors (among others ANGPTL4, VEGFA, PGF) (for references see Table
2). Supporting our in vitro data, previous in vivo data conﬁrm that ANG,
VEGF, and IL-16 play a role in multiple myeloma and are detectable in
plasma cell inﬁltrated bone marrow [48,49]. Our data show that the
transcriptome of skeletal precursor cells changes with regard to an en-
hanced osteoclast-activating potential within hours of physical contact
withmyeloma cells. In addition to an enhanced activation of osteoclasts,
myeloma bone disease is characterized by a hampered osteogenic dif-
ferentiation potential of MSC and enhanced production of angiogenic
factors that is, according to this study, also triggered in MSC early after
INA-6 cell contact. The whole-genome analysis may provide novel tar-
gets and mechanisms, which result in blunted osteogenic potential.
These include, for example, the expression of genes that code for osteo-
clastic proteins, such as semaphorin 4D and ephrin-B2 [50,51] and a lost
expression of anabolic factors, indicated by downregulation of OMD in
INA-6 cell co-cultured MSC. In addition, we detected a cluster of
genes, possibly indicating a switch to a more lipogenic phenotype.
Whether an adipogenic lineage commitment is favored in MSC and
OPC at the expense of osteogenic regeneration remains to be proven,
but has already been considered to play a role in theMM pathophysiol-
ogy [52]. Although the whole genome analysis is limited to INA-6 cell
co-cultured bone-forming cells, this lists may harbor a number of tar-
gets and mechanisms that are frequently or even generally involved in
Fig. 3.Validation of differential gene expression inMSC andOPC after INA-6 cell contact. Microarray results were re-evaluated by examining the expression of 11 genes thatwere selected
from the (A)MSC and (B)OPCmicroarray lists. Differential expression of the geneswas validated using sequence-speciﬁc primer pairs, semi-quantitative RT-PCR, and cDNA from the same
RNA specimens that had been used for gene chip hybridization prior to this. For quantitation, PCR products were analyzed densitometrically and normalized to the housekeeping gene
EEF1A1. Representative agarose gel pictures and bar graphs, displaying the amount of ampliﬁed PCR products are shown. Bar graphs display mean transcript levels ±SEM, n = 5. The
basal expression level (black bar; control) was set to 1 while the respective changes of the mRNA levels in the co-cultured specimens are depicted as white bars. Statistic was
performed with two-tailed Mann-Whitney test, analyzing the differences in expression levels between control cells (−) and cells after co-culture (+). Statistically signiﬁcant
differences are indicated by ** if the p-value was ≤0.01. Gene symbols and descriptions are listed in Supplemental Table 1.
162 J. Dotterweich et al. / Bone 93 (2016) 155–166myeloma bone disease initiation and progression and are worth further
investigation. The list of differentially regulated probe sets included a
high number of geneswith a putative impact on regulation of angiogen-
esis, for example the KISS1R (reviewed in [53,54]). Being the highest
upregulated gene of the OPC array validation, the KISS1R was recentlypublished as an in vivo imaging biomarker of MM bone disease [30].
As a second signiﬁcantly regulated gene involved in angiogenesis, we
focused on ANGPTL4 (reviewed in [55]) since this gene has been
shown to be differentially expressed in MSC isolated fromMM patients
[17,41]. We were able to show a signiﬁcant upregulation of ANGPTL4
Table 2
Differential expression of genes in skeletal precursor cells after 24 h INA-6 cell contact that may contribute to MM disease progression.
Symbol Gene name log-Fc
MSC
log-Fc
OPC
Reference
2.1. Homing
CCL26 Chemokine (C\\C motif) ligand 26 1.0 CCL26 activates chemokine (C\\C motif) Receptor (CCR) 3, expressed on MM cells. [73,74]
CCL28 Chemokine (C\\C motif) ligand 28 1.5 1.5 Expressed by bone marrow stromal cells and possibly involved in the homing of plasma
cells to bone marrow by binding to CCR3 and CCR10.
[74]
2.2 Adhesion
ICAM1 Intercellular adhesion molecule 1 1.2 ICAM1 is a ligand for the leukocyte adhesion protein LFA-1, expressed on MM cells.
Upregulated in osteoblasts after co-culture with myeloma cells. ICAM1/LFA-1 system
may mediate apoptogenic signaling.
[39,75]
ICAM5 Intercellular adhesion molecule 5,
telencephalin
1.2 ICAM5 is a ligand for LFA-1. [40]
COL11A1 Collagen, type XI, alpha 1 1.3 Upregulated in osteoclasts co-cultured with myeloma cells. [76]
JAM2 Junctional adhesion molecule 2 2.2 Jam2/3 interaction mediates adhesion between lung endothelial cells and melanoma
cells, favoring metastasis of tumor cells to the lungs.
[77]
2.3 Angiogenesis
ANG Angiogenin, ribonuclease, RNase A family, 5 1.8 ANG shows activity in in vitro angiogenesis assay. It activates inositol-speciﬁc
phospholipase C in endothelial cells.
[78]
APLN Apelin 1.1 APLN shows angiogenic activity in an in vitro angiogenesis assay using retinal endothelial
cells.
[79]
STC1 Stanniocalcin-1 2.2 STC1 exerts angiogenesis by inducing expression of VEGF in gastric cancer cells. [80]
VEGFA Vascular endothelial growth factor A 2.2 2.0 Ligand of Flk-1. Plays a role in blood vessel formation. [81]
ANGPTL4 Angiopoietin-like 4 3.0 2.0 ANGPTL4 mediates VEGF-independent angiogenesis. [82]
PGF Placental growth factor 1.3 1.2 PGF is a ligand for VEGF receptors, like Flt-1, and enhance bioactivity of VEGF. [83]
NRN1 Neuritin 1 1.7 NRN1 is a neurotrophic factor that exerts also angiogenic function in vitro and in vivo. [84]
2.4 Adipogenesis and lipid metabolism
ZNF395 Zinc Finger Protein 395 3.0 2.2 ZNF395 has a pro-adipogenic role. ZNF395 enhances adipogenic differentiation from
dermal ﬁbroblasts in concert with proliferator-activated receptor γ (PPARγ) 2.
[86]
KLF8 Kruppel-like factor 8 1.2 Expression of transcription factor KLF8 is enhanced in 3T3-L1 cells that underwent
adipogenic differentiation, upstream of PPARγ and CCAAT/enhancer-binding protein α
(C/EBPα).
[87]
KLF9 Kruppel-like factor 9 1.1 Expression of transcription factor KLF9 is upregulated in 3T3-L1 cells that underwent
adipogenic differentiation. KLF9 is upstream of PPARγ.
[88]
CEBPD CCAAT/enhancer binding protein (C/EBP),
delta
1.3 Induced in the early phase of adipogenic differentiation. [89]
ANGPTL4 Angiopoietin-like 4 3.0 2.0 Inhibits lipoprotein lipase and regulates triglyceride metabolism. ANGPTL4 expression is
induced by PPAR and transforming growth factor-β ligands.
[90,91]
APLN Apelin 1.1 APLN is an adipokine, which expression is regulated by insulin. [92]
PLIN2 Perilipin 2 1.8 1.2 PLIN2 is a member of the Perilipin family, involved in lipid storage. [93]
HILPDA Hypoxia inducible lipid droplet-associated 3.1 Target gene of HIF-1. HILPDA overexpression potentiates intracellular lipid accumulation
and expression of VEGFA, migration inhibitory factor, and IL-6.
[94]
ABCA1 ATP-binding cassette, sub-family A (ABC1),
member 1
2.4 Cell-membrane transporter of lipophilic molecules, like cholesterol and phospholipids. [85]
VLDLR Very low density lipoprotein receptor 3.4 2.1 VLDLR is involved in cholesterol uptake. [95]
PTGS2 Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
1.0 PTGS2 is involved in prostaglandin E2 synthesis. [96]
PTGES Prostaglandin E synthase 1.8 PTGES is involved in prostaglandin E2 synthesis. [96]
PLCG2 Phospholipase C, gamma 2
(phosphatidylinositol-speciﬁc)
1.1 PLCG2 is involved in prostaglandin E2 synthesis. [97]
Fc = Fold change.
log-Fc MSC= log-Fc in array “MSC after INA-6 cell contact”.
log-Fc OPC = log-Fc in array “OPC after INA-6 cell contact”.
Indicated is the most differentially regulated probe set of the corresponding gene.
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OPM-2 cells. According to our studies, the upregulation of ANGPTL4
mRNA is not universal for B-cell contact, at least not for CD19+ B-
cells. However, whether or not this induction in bone-forming cells
is exclusively mediated by malignant B-cell contact remains to be
proven by studies comprising other B-cell subpopulations, e.g. ma-
ture plasma cells.
Since ANGPTL4 is an extracellular matrix protein [42], a potential
role in adhesion ofMMcells toMSC seemed likely.Wewere able to con-
ﬁrm an enhanced number of attached INA-6 cells to ANGPTL4-coated
wells, implicating a potential role of ANGPTL4 in mediating cell-cell in-
teraction. However, this adhesion attitude is diminished in long-term
cultures of INA-6 cells (data not shown).
Presence of key factors like ANGPTL4 may mediate a disconnection
between osteoblastogenesis and angiogenesis in myelomatous bones,different to the healthy counterpart where angiogenesis is tightly
coupled with osteogenesis [56]. A consistent, increased serum level of
ANGPTL4 and RANKL, a serum marker of bone resorption, has already
been described for rheumatoid arthritis patients [57]. In addition, our
group has shown that ANGPTL4 is differentially expressed in the MSC
transcriptome of osteoporotic patients [35] – reinforcing a potential
role of this protein in pathological bone loss. Whether ANGPTL4
serum levels correlate with osteolytic bone loss in myeloma and in-
crease during the course of disease has to be evaluated. However, mea-
surement of this protein in patient's serummay be an alternative to the
measurement of the bone resorption biomarker RANKL, which is affect-
ed by treatment with anti-catabolic agents, like denosumab. The more
in-depth evaluation of this gene product may represent another proof
that mRNA changes are in fact followed by translational and functional
consequences.
Fig. 4. ANGPTL4 expression inMSC after co-culturewith INA-6 cells and CD19+ B-cells. Levels of ANGPTL4mRNA inMSC after 24 h of (A) direct and indirect co-culturewith INA-6 cells and
(B) direct co-culture with CD19+ B-cells (n = 3). In case of direct co-culture, INA-6 and B-cells were depleted from MSC by MACS using CD45 and CD19 MicroBeads, respectively.
Respective controls were treated accordingly. Expression of ANGPTL4 was determined with semi-quantitative RT-PCR by using densitometric analysis and normalization to levels of
EEF1A1mRNA. Bar graphs display the mean transcript levels ±SEM. Statistic was performed with non-parametric Kruskal-Wallis and Dunn's post-hoc multiple comparison tests (Fig.
4A) as well as two-tailed Mann-Whitney test (Fig. 4B). Differences were considered to be signiﬁcant if the p-value was ≤0.05 (*).
164 J. Dotterweich et al. / Bone 93 (2016) 155–166In summary, we identiﬁed a characteristic genomic signature in
skeletal precursor cells after 24 h physical interactionwith themyeloma
cell line INA-6. The transcriptome analyses reﬂect changes in the gene
expression proﬁles that have previously been linked to malignancy
and are supporting a tumor-induced bone loss. According to the analy-
sis, intrinsic pro-osteogenic pathways are downregulated in MSC that
may be mediated by enhanced expression of osteoclast-derived cou-
pling factors, an imbalanced ratio of anti-anabolic/anabolic factors, and
a potential commitment to the adipocyte lineage. Furthermore, this
hampered osteogenesis is associated with enhanced pro-angiogenic ac-
tivity. This uncoupling between angiogenesis and osteogenesis may be
triggered by an enhanced expression of key factors, like ANGPTL4,
which further promote MM cell adhesion. These data reveal novel, po-
tential trigger mechanisms and targets that trace the early processes
of myeloma bone disease and offer new opportunities in the treatment
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